Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals Inc (NQ: ELDN )

2.820 -0.070 (-2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 189,162
Open 2.880
Bid (Size) 2.460 (102)
Ask (Size) 2.770 (1)
Prev. Close 2.890
Today's Range 2.570 - 2.890
52wk Range 1.070 - 3.349
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+50.00%
+50.00%
1 Month
+30.56%
+30.56%
3 Month
+54.95%
+54.95%
6 Month
+138.98%
+138.98%
1 Year
+70.91%
+70.91%

More News

Read More
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Expert Ratings for Eledon Pharma
Via Benzinga
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
Via InvestorPlace
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
Via Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.